一分钟看懂
这是一项关于鼻咽癌的I 期 / II 期研究，登记的药物或干预包括BL-M08D1，当前状态为尚未开始招募。登记地点显示中国重庆、广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BL-M08D1 · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Chongqing University Cancer Hospital · 重庆
- Sun Yat-sen University Cancer Center · 广州
公开的入选条件
- 1. Voluntarily sign the informed consent form and agree to comply with the protocol requirements;
- 2. No gender restriction;
- 3. Age: ≥18 years and ≤75 years;
- 4. Expected survival time ≥3 months;
- 5. Recurrent or metastatic nasopharyngeal carcinoma and other solid tumors;
- 6. Agree to provide archived tumor tissue specimens or fresh tissue samples from the primary or metastatic lesions within 3 years;
- 7. Must have at least one measurable lesion as defined by RECIST v1.1;
- 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with no deterioration within 2 weeks prior to the first dose;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07818486；登记信息更新于 2026-09-14。